Site Map

  CEL-SCI Home Page  
       
  o About CEL-SCI  
   
       
  o History  
       
  o Mission and Values  
       
  o Business Strategy  
       
  o Corporate Overview  
   
       
  o Privacy Policy  
       
 
  o Corporate Headquarters  
       
  o Company Code of Ethics  
       
  o Management Team  
       
 
  o Products  
   
       
  o Cancer-MultikineŽ  
   
       
  o Introduction to Cancer Immunotherapy  
       
  o Types of Biological Cancer Immunotherapy  
   
     
  Passive Immunotherapy  
     
  Active Immunotherapy  
     
  Comprehensive Immunotherapy  
     
 
  o Limitations of Current Immunotherapies  
       
  o What is MultikineŽ?  
   
     
  Introduction to MultikineŽ  
     
  MultikineŽ is the first Immune SIMULATOR:
A new class of immunotherapy drugs
 
     
  MultikineŽ's uses, efficacy and clinical trial status  
     
  MultikineŽ Tumor Pictures  
     
  MultikineŽ Phase III Clinical Trial Design  
     
  MultikineŽ Mechanism of Action  
     
  MultikineŽ Key benefits  
     
  Head and Neck Cancer  
     
  Cigarette Smoking and Cancer: Q&A  
     
 
 
  o Infectious Diseases-L.E.A.P.S.(TM)  
   
       
  o Introduction and Overview  
       
  o Summary of L.E.A.P.S.(TM) and CEL-1000 Collaborators  
       
  o L.E.A.P.S.(TM) Scientific Backgrounder  
       
  o Background on CEL-1000  
       
 
 
  o Research & Clinical Trials  
       
  o Investor Relations  
   
       
  o SEC Filings  
       
  o Stock Quotes  
       
  o Letter to Shareholders  
       
  o Special Highlights  
       
 
  o Scientific Publications/Presentations  
       
  o News & Announcements  
   
       
  o Press Releases  
       
   
       
  o Sign Up for News  
       
 
  o Recent Media Coverage  
  o Careers  
   
       
  o Job Postings  
       
 
  o Hear from Others about CEL-SCI  
       
  o CEL-SCI CORPORATION Manufacturing Facility